Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 CPT code 79101

Radiopharmaceutical therapy, by intravenous administration.

Follow CPT coding guidelines for nuclear medicine procedures. When reporting the professional component only, use modifier 26. For the technical component only, use modifier TC.

Modifiers 26 (professional component), TC (technical component), 52 (reduced services), 76, 77, 79, 80, 81, 82, 99, AQ, AS, GC, GR, KX, PD, and Q6 can be applied when appropriate.

Medical necessity must be established for the use of radiopharmaceutical therapy. Documentation should support the medical rationale for this treatment approach.

Administering the radiopharmaceutical intravenously. The physician is also responsible for the patient's overall care, including diagnosis, treatment planning, and follow-up.

IMPORTANT:Do not report 79101 in conjunction with 36400, 36410, 79403, 96360, 96374 or 96375, 96409. For radiolabeled monoclonal antibody by intravenous infusion, use 79403. For infusion or instillation of non-antibody radioelement solution that includes 3 months follow-up care, use 77750.

In simple words: This procedure involves injecting a radioactive material into your vein to treat a medical condition, usually cancer. The substance travels throughout your body to target and destroy affected cells. The cost of the radioactive material itself is billed separately.

This code represents the intravenous administration of a radiopharmaceutical for therapeutic purposes. It does not include the supply of the radiopharmaceutical itself, which should be billed separately. The code also excludes any related diagnostic workup, follow-up care, or procedures like intra-arterial administration, which require additional coding.

Example 1: A patient with thyroid cancer receives radioactive iodine (I-131) intravenously to destroy cancerous thyroid cells., A patient with bone pain due to metastatic prostate cancer receives Samarium-153 intravenously for pain palliation., A patient with non-Hodgkin's lymphoma receives radioactive Yttrium-90-labeled antibodies intravenously as part of their treatment.

Documentation should include the type and dose of radiopharmaceutical administered, the route of administration, the diagnosis being treated, and any pre- and post-administration care provided.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.